Akebia Therapeutics, Inc. (AKBA)
AKBA moved a median of 0.00% 30 minutes after news, and +0.47% by the close. How AKBA actually reacts to news — the realized, point-in-time move the market made, measured across 377 labeled events over the last three years with zero look-ahead.
AKBA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.21% | 42% | 377 |
| 30-min | 0.00% | 49% | 377 |
| 60-min | +0.32% | 53% | 377 |
| to close | +0.47% | 52% | 373 |
| Middle 50% of AKBA reactions | -1.57% to +1.44% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 377 |
Half of all Akebia Therapeutics, Inc. news events land between -1.57% and +1.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AKBA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 16 | -0.40% | 38% | -0.62% |
| Analyst downgrades | 18 | -0.52% | 39% | -0.85% |
| Coverage initiations | 12 | -2.25% | 42% | -1.01% |
| Rating reiterations | 42 | +0.33% | 55% | +0.39% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how AKBA ranks against every other measured name →
That’s how AKBA usually reacts — get an email when it moves on news →Email me when AKBA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AKBA's baseline. Nothing else.
Recent AKBA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Akebia Therapeutics, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | — | |
| Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum | Press release | GlobeNewswire | +0.58% | +1.17% | |
| Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026 | Press release | GlobeNewswire | -0.95% | -2.55% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.90% | -2.59% | |
| Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases | Press release | GlobeNewswire | +0.29% | +1.15% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +4.74% | +3.19% | |
| Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston | Press release | GlobeNewswire | +1.52% | +3.83% | |
| Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | +7.13% | +8.20% | |
| Form 10-Q Akebia Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.13% | +8.20% | |
| Form 8-K Akebia Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +7.13% | +8.20% | |
| Form S-8 Akebia Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +7.13% | +8.20% | |
| Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases | Press release | GlobeNewswire | -0.76% | +0.00% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.76% | +0.76% | |
| Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights | Press release | GlobeNewswire | +1.19% | +0.00% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.78% | +4.00% | |
| Form 8-K Akebia Therapeutics, For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -6.31% | -10.24% | |
| U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA | Press release | GlobeNewswire | -6.31% | -10.24% | |
| Form 8-K Akebia Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.38% | +0.92% | |
| Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio | Press release | GlobeNewswire | -0.15% | -5.12% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.49% | -7.29% | |
| Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -0.96% | +0.96% | |
| Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights | Press release | GlobeNewswire | +3.98% | +4.42% | |
| Form 10-Q Akebia Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.98% | +4.42% | |
| Form 8-K Akebia Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +3.98% | +4.42% | |
| Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology | Press release | GlobeNewswire | +3.90% | +6.38% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.66% | -4.61% | |
| Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights | Press release | GlobeNewswire | +0.36% | +0.00% | |
| Form ARS Akebia Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.43% | -2.86% | |
| Form DEF 14A Akebia Therapeutics, For: Apr 28 | SEC filing · Form DEF | SEC EDGAR | -1.43% | -2.86% | |
| Form DEFA14A Akebia Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.43% | -2.86% | |
| Form PRE 14A Akebia Therapeutics, For: Apr 15 | SEC filing · Form PRE | SEC EDGAR | -0.97% | -12.34% | |
| Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 | Press release | GlobeNewswire | +0.36% | +5.00% | |
| Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium | Press release | GlobeNewswire | -0.37% | +2.22% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.72% | -5.04% | |
| Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors | Press release | GlobeNewswire | -0.72% | -0.72% | |
| Form 8-K Akebia Therapeutics, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | -0.72% | |
| Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 | Press release | GlobeNewswire | +0.35% | +0.00% | |
| Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference | Press release | GlobeNewswire | +0.33% | -0.81% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.33% | -0.81% | |
| Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights | Press release | GlobeNewswire | -7.19% | -9.59% | |
| Form 10-K Akebia Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -7.19% | -9.59% | |
| Form 8-K Akebia Therapeutics, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -7.19% | -9.59% | |
| Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights | Press release | GlobeNewswire | -1.27% | +0.00% | |
| Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | -0.70% | -3.52% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.36% | +1.44% | |
| Form 8-K Akebia Therapeutics, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | -4.08% | |
| Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook | Press release | GlobeNewswire | -6.04% | -6.04% | |
| Form 8-K Akebia Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -6.04% | -6.04% | |
| Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) | Press release | GlobeNewswire | -0.67% | -2.00% | |
| Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.67% | -2.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AKBA section they belong to.
Where else AKBA is measured.
AKBA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Albireo Pharma, Inc. (ALBO) | 378 | +0.05% | 53% |
| REPRO MED SYSTEMS INC (REPR) | 378 | 0.00% | 26% |
| Amneal Pharmaceuticals, Inc. - Class A (AMRX) | 377 | -0.08% | 46% |
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Akebia Therapeutics, Inc.'s median reaction calculated?
Every labeled AKBA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 377 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of AKBA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AKBA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.